Efficacy of varenicline, an alpha4ß2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial [corrected] [published erratum appears in JAMA 2006 Sep 20;296(11):1355].
Saved in:
| Title: | Efficacy of varenicline, an alpha4ß2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial [corrected] [published erratum appears in JAMA 2006 Sep 20;296(11):1355]. |
|---|---|
| Authors: | Jorenby DE (AUTHOR), Hays JT (AUTHOR), Rigotti NA (AUTHOR), Azoulay S (AUTHOR), Watsky EJ (AUTHOR), Williams KE (AUTHOR), Billing CB (AUTHOR), Gong J (AUTHOR), Reeves KR (AUTHOR), Varenicline Phase 3 Study Group (CORPORATE AUTHOR), Jorenby, Douglas E1 (AUTHOR), Hays, J Taylor (AUTHOR), Rigotti, Nancy A (AUTHOR), Azoulay, Salomon (AUTHOR), Watsky, Eric J (AUTHOR), Williams, Kathryn E (AUTHOR), Billing, Clare B (AUTHOR), Gong, Jason (AUTHOR), Reeves, Karen R (AUTHOR) |
| Source: | JAMA: Journal of the American Medical Association. 7/5/2006, Vol. 296 Issue 1, p56-63. 8p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
